Skip to main content
Erschienen in: International Journal of Hematology 3/2018

08.05.2018 | Original Article

Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia

verfasst von: Nanami Gotoh, Takayuki Saitoh, Noriyuki Takahashi, Tetsuhiro Kasamatsu, Yusuke Minato, Alkebsi Lobna, Tsukasa Oda, Takumi Hoshino, Toru Sakura, Hiroaki Shimizu, Makiko Takizawa, Hiroshi Handa, Akihiko Yokohama, Norifumi Tsukamoto, Hirokazu Murakami

Erschienen in: International Journal of Hematology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Recent studies have shown that tumors of relapsed acute myeloid leukemia (AML) present additional genetic mutations compared to the primary tumors. The base excision repair (BER) pathway corrects oxidatively damaged mutagenic bases and plays an important role in maintaining genetic stability. The purpose of the present study was to investigate the relationship between BER functional polymorphisms and AML relapse. We focused on five major polymorphisms: OGG1 S326C, MUTYH Q324H, APE1 D148E, XRCC1 R194W, and XRCC1 R399Q. Ninety-four adults with AML who achieved first complete remission were recruited. Genotyping was performed with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The OGG1 S326C CC genotype (associated with lower OGG1 activity) was observed more frequently in patients with AML relapse [28.9 vs. 8.9%, odds ratio (OR) = 4.10, 95% confidence interval (CI) = 1.35–12.70, P = 0.01]. Patients with the CC genotype exhibited shorter relapse-free survival (RFS). Moreover, the TCGA database suggested that low OGG1 expression in AML cells is associated with a higher frequency of mutations. The present findings suggest that the OGG1 S326C polymorphism increased the probability of AML relapse and may be useful as a prognostic factor for AML relapse risk.
Literatur
1.
Zurück zum Zitat Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.CrossRefPubMedPubMedCentral Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D, et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood. 2013;121:369–77.CrossRefPubMedPubMedCentral Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D, et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood. 2013;121:369–77.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Hiraoka W, Vazquez N, Nieves-Neira W, Chanock SJ, Pommier Y. Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest. 1998;102:1961–8.CrossRefPubMedPubMedCentral Hiraoka W, Vazquez N, Nieves-Neira W, Chanock SJ, Pommier Y. Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest. 1998;102:1961–8.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Tada-Oikawa S, Oikawa S, Kawanishi M, Yamada M, Kawanishi S. Generation of hydrogen peroxide precedes loss of mitochondrial membrane potential during DNA alkylation-induced apoptosis. FEBS Lett. 2009;442:65–9.CrossRef Tada-Oikawa S, Oikawa S, Kawanishi M, Yamada M, Kawanishi S. Generation of hydrogen peroxide precedes loss of mitochondrial membrane potential during DNA alkylation-induced apoptosis. FEBS Lett. 2009;442:65–9.CrossRef
5.
Zurück zum Zitat Varbiro G, Veres B, Gallyas F Jr, Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med. 2001;31:548–58.CrossRefPubMed Varbiro G, Veres B, Gallyas F Jr, Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med. 2001;31:548–58.CrossRefPubMed
6.
Zurück zum Zitat Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 2005;76:1439–53.CrossRefPubMed Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 2005;76:1439–53.CrossRefPubMed
8.
Zurück zum Zitat Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci. 2009;66:981–93.CrossRefPubMed Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci. 2009;66:981–93.CrossRefPubMed
9.
Zurück zum Zitat Simonelli V, Mazzei F, D’Errico M, Dogliotti E. Gene susceptibility to oxidative damage: from single nucleotide polymorphisms to function. Mutat Res. 2012;731:1–13.CrossRefPubMed Simonelli V, Mazzei F, D’Errico M, Dogliotti E. Gene susceptibility to oxidative damage: from single nucleotide polymorphisms to function. Mutat Res. 2012;731:1–13.CrossRefPubMed
10.
Zurück zum Zitat Yamane A, Kohno T, Ito K, Sunaga N, Aoki K, Yoshimura K, Murakami H, et al. Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. Carcinogenesis. 2004;25:1689–94.CrossRefPubMed Yamane A, Kohno T, Ito K, Sunaga N, Aoki K, Yoshimura K, Murakami H, et al. Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. Carcinogenesis. 2004;25:1689–94.CrossRefPubMed
11.
Zurück zum Zitat Kuriyama K, Tomonaga M, Kobayashi T, Nishikawa K, Ohshima T, Furusawa S, et al. Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML. In: Hiddemann W, Büchner T, Wörmann, editors. Acute leukemias VII: experimental approaches and novel therapies. New York: Springer; 1998. pp. 901–5.CrossRef Kuriyama K, Tomonaga M, Kobayashi T, Nishikawa K, Ohshima T, Furusawa S, et al. Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML. In: Hiddemann W, Büchner T, Wörmann, editors. Acute leukemias VII: experimental approaches and novel therapies. New York: Springer; 1998. pp. 901–5.CrossRef
12.
Zurück zum Zitat Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Brit J Haematol. 1999;107:69–79.CrossRef Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Brit J Haematol. 1999;107:69–79.CrossRef
13.
Zurück zum Zitat Miyawaki S. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). Int J Hematol. 2017;106:310–25.CrossRefPubMed Miyawaki S. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). Int J Hematol. 2017;106:310–25.CrossRefPubMed
14.
Zurück zum Zitat Yamane A, Shinmura K, Sunaga N, Saitoh T, Yamaguchi S, Shinmura Y, et al. Suppressive activities of OGG1 and MYH proteins against G:C to T:A mutations caused by 8-hydroxyguanine but not by benzo[a]pyrene diol epoxide in human cells in vivo. Carcinogenesis. 2003;24:1031–7.CrossRefPubMed Yamane A, Shinmura K, Sunaga N, Saitoh T, Yamaguchi S, Shinmura Y, et al. Suppressive activities of OGG1 and MYH proteins against G:C to T:A mutations caused by 8-hydroxyguanine but not by benzo[a]pyrene diol epoxide in human cells in vivo. Carcinogenesis. 2003;24:1031–7.CrossRefPubMed
15.
Zurück zum Zitat Bravard A, Vacher M, Moritz E, Vaslin L, Hall J, Epe B, et al. Oxidation status of human OGG1-S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res. 2009;69:3642–9.CrossRefPubMed Bravard A, Vacher M, Moritz E, Vaslin L, Hall J, Epe B, et al. Oxidation status of human OGG1-S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res. 2009;69:3642–9.CrossRefPubMed
16.
Zurück zum Zitat Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 2003;112:1751–61.CrossRefPubMedPubMedCentral Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 2003;112:1751–61.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Liddiard K, Hills R, Burnett AK, Darley RL, Tonks A. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene. 2010;29:2005–10.CrossRefPubMed Liddiard K, Hills R, Burnett AK, Darley RL, Tonks A. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene. 2010;29:2005–10.CrossRefPubMed
18.
Zurück zum Zitat Preston TJ, Henderson JT, McCallum GP, Wells PG. Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Mol Cancer Ther. 2009;8:2015–26.CrossRefPubMedPubMedCentral Preston TJ, Henderson JT, McCallum GP, Wells PG. Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Mol Cancer Ther. 2009;8:2015–26.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Bacsi A, Chodaczek G, Hazra TK, Konkel D, Boldogh I. Increased ROS generation in subsets of OGG1 knockout fibroblast cells. Mech Ageing Dev. 2007;128:637–49.CrossRefPubMedPubMedCentral Bacsi A, Chodaczek G, Hazra TK, Konkel D, Boldogh I. Increased ROS generation in subsets of OGG1 knockout fibroblast cells. Mech Ageing Dev. 2007;128:637–49.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006;10(3):175–6.CrossRefPubMed Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006;10(3):175–6.CrossRefPubMed
21.
Zurück zum Zitat Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K, et al. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2011;25:1423–32.CrossRefPubMed Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K, et al. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2011;25:1423–32.CrossRefPubMed
22.
Zurück zum Zitat Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-α, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Adult Urol. 2005;65:70–5.CrossRef Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-α, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Adult Urol. 2005;65:70–5.CrossRef
23.
Zurück zum Zitat Kim EJ, Yan C, Ha YS, Jeong P, Yi Kim I, Moon SK, et al. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urol Oncol. 2012;30:673–9.CrossRefPubMed Kim EJ, Yan C, Ha YS, Jeong P, Yi Kim I, Moon SK, et al. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urol Oncol. 2012;30:673–9.CrossRefPubMed
Metadaten
Titel
Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia
verfasst von
Nanami Gotoh
Takayuki Saitoh
Noriyuki Takahashi
Tetsuhiro Kasamatsu
Yusuke Minato
Alkebsi Lobna
Tsukasa Oda
Takumi Hoshino
Toru Sakura
Hiroaki Shimizu
Makiko Takizawa
Hiroshi Handa
Akihiko Yokohama
Norifumi Tsukamoto
Hirokazu Murakami
Publikationsdatum
08.05.2018
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2018
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2464-9

Weitere Artikel der Ausgabe 3/2018

International Journal of Hematology 3/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.